middle.news
Anteris Secures $90M Medtronic Backing to Propel DurAVR Heart Valve Trial
9:48am on Friday 23rd of January, 2026 AEDT
•
Healthcare
Read Story
Anteris Secures $90M Medtronic Backing to Propel DurAVR Heart Valve Trial
9:48am on Friday 23rd of January, 2026 AEDT
Key Points
Medtronic invests $90 million in Anteris as part of $320 million capital raise
Funding supports global PARADIGM trial for DurAVR transcatheter heart valve
PARADIGM trial is a randomized controlled study comparing DurAVR to existing TAVR devices
DurAVR designed with patented biomimetic ADAPT tissue technology
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE